Radius Health, Inc. (RDUS) |
|
10.08 0 (0%)
|
12-31 19:00 |
|
Open: |
10.1 |
Pre. Close: |
10.08 |
|
High:
|
10.18 |
Low:
|
10.065 |
|
Volume:
|
6,485,423 |
Market Cap:
|
0(M) |
|
|
|
Technical analysis |
as of: 2022-11-18 4:24:13 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 11.83 One year: 11.89 |
| Support: |
Support1: 10.06 Support2: 8.37 |
| Resistance: |
Resistance1: 10.13 Resistance2: 10.18 |
| Pivot: |
10.07 |
| Moving Average: |
MA(5): 10.07 MA(20): 10.07
MA(100): 10.1  MA(250): 8.76 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 13 %D(3): 13 |
| RSI: |
RSI(14): 57 |
| 52-week: |
High: 17.7 Low: 4.96 |
| Average Vol(K): |
3-Month: 6,485 (K) 10-Days: 6,485 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ RDUS ] has closed Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 90 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
10.2 - 10.25 |
10.25 - 10.29 |
|
Low:
|
9.92 - 9.99 |
9.99 - 10.05 |
|
Close:
|
9.98 - 10.09 |
10.09 - 10.17 |
|
Company Description |
|
Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts. As of August 10, 2022, Radius Health, Inc. was taken private. |
Headline News |
Mon, 15 Aug 2022
This Top Insider is Bulking up on Radius Health Stock - TipRanks
Mon, 15 Aug 2022
Gurnet Point Capital and Patient Square Capital Complete Their Acquisition of Radius Health, Inc. - Yahoo Finance
Thu, 07 Jul 2022
Radius Health Publishes Investor Presentation Outlining Company’s Progress and Board Process Resulting in Agreement to be Acquired at Significant Premium - Yahoo Finance
Fri, 24 Jun 2022
Radius (RDUS) to Go Private With $890M Deal, Shares Gain - Nasdaq
Thu, 23 Jun 2022
RDUS stock jumps on $890M buyout offer (NASDAQ:RDUS) - Seeking Alpha
Thu, 23 Jun 2022
Radius Health Announces Agreement to be Acquired by Gurnet ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Drug Manufacturers—Specialty & Generic |
| Shares Out. |
0 (M) |
| Shares Float |
0 (M) |
|
% Held by Insiders
|
0 (%) |
|
% Held by Institutions
|
0 (%) |
|
Shares Short
|
0 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
0 |
|
EPS Est Next Qtl
|
-1.26 |
|
EPS Est This Year
|
-5.41 |
|
EPS Est Next Year
|
-3.93 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
0 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
4.47 |
|
Sales Per Share
|
4.58 |
|
EBITDA (p.s.)
|
-1.06 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
0 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
2.2 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
